Recent news on Simulect

Cerimon Pharmaceuticals Names Ayse Kocak Vice President of Marketing  -  Apr 12, 2007
Drug Newswire (press release),The Company currently has two drugs in development, a topical formulation of diclofenac sodium for the treatment of osteoarthritis pain and Simulect for

Cerimon Pharmaceuticals Initiates ARREST UC-1, A Global Phase 2b ...  -  Apr 5, 2007
Medical News Today (press release),Inc., announced today it has begun enrolling patients in a Phase 2b clinical study, for its lead product candidate basiliximab (Simulect(R)),

Cerimon Pharmaceuticals Initiates ARREST UC-1, a Global Phase 2b ...  -  Apr 4, 2007
PharmaLive.com (press release),NOTE: Simulect(R) is a registered product of Novartis Pharma AG. CONTACT: Jim Welch, Chief Financial Officer of Cerimon Pharmaceuticals,+1-650-827-4000,

Cerimon Pharmaceuticals Initiates ARREST UC-1, a Global Phase 2b ...  -  Apr 4, 2007
PR-Inside.com (Pressemitteilung),For more information on Cerimon, please visit the company's website at http://www.cerimon.com/. NOTE: Simulect(R) is a registered product of Novartis Pharma

Cerimon Pharmaceuticals Names Daniel Levitt, MD, Ph.D. Executive ...  -  Jan 8, 2007
PR Newswire (press release),Dr. Levitt will direct Cerimon's product development activities and manage the Company's clinical programs for its lead product candidate, Simulect(R),

Cerimon Pharmaceuticals Names Ayse Kocak Vice President of Marketing  -  Dec 5, 2006
Drug Newswire (press release),The Company currently has two drugs in development, a topical formulation of diclofenac sodium for the treatment of osteoarthritis pain and Simulect for

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional